ACL australian clinical labs limited

ACL, page-2

  1. 1,100 Posts.
    lightbulb Created with Sketch. 151
    lots of COVID testing going on and for at least a year which certainly will affect earnings. Organic acquisitions all from cash flow/debt and are insignificant on the balance sheet due to low debt/equity ratio. Strong buy however it's a defensive stock so $4.25-50 price target and will stay there for at least a year without much more appreciation thereafter . yield roughly 3.9% allowing for COVID testing profit increase DYOR
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$2.80
Change
-0.020(0.71%)
Mkt cap ! $549.8M
Open High Low Value Volume
$2.83 $2.85 $2.79 $1.298M 461.9K

Buyers (Bids)

No. Vol. Price($)
2 51758 $2.79
 

Sellers (Offers)

Price($) Vol. No.
$2.80 92945 3
View Market Depth
Last trade - 16.10pm 30/07/2025 (20 minute delay) ?
ACL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.